Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Recruiting now · Phase 3

Conditions studied: Hepatocellular Carcinoma

In brief

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy

Key facts

Study ID

NCT06921785

Run by

AstraZeneca

People needed

1220

Starts

2025-05-06

Expected to finish

2030-03-15

Last updated by the study team

2026-07-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Locally advanced or metastatic and/or unresectable HCC
• WHO/ECOG performance status of 0 or 1
• BCLC stage B (that is not eligible for locoregional therapy) or stage C.
• Child-Pugh Score class A
• At least one measurable target lesion
• Participants with active HBV infection must receive antiviral therapy for a minimum of 14 days prior to randomization to show evidence of HBV stabilization or signs of viral response.
• Participants with active HCV infection must be well controlled. Participants co-infected with HBV and HCV are not eligible.
• Adequate organ and bone marrow function measured during the screening period.
• Adequate organ and bone marrow function measured during the screening period
• Must not have received prior systemic therapy for intermediate, advanced, or metastatic HCC.
• Disease that is not amenable to curative surgical and/or locoregional therapies. For participants who received locoregional therapy for HCC, locoregional therapy must have been completed ≥ 28 days prior to the baseline scan for the current study.

You may not qualify if…

• Medical condition
• Any evidence of uncontrolled intercurrent diseases
• Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment
• History of another primary malignancy
• Persistent toxicities caused by previous anti-cancer therapy excluding alopecia, not yet improved to Grade ≤ 1 or baseline.
• Clinically meaningful ascites, pleural effusion, or pericardial effusion requiring non-pharmacologic intervention to maintain symptomatic control within 6 months prior to the first scheduled dose.
• History of active primary immunodeficiency or active infection
• History of hepatic encephalopathy
• Current or recent (within 10 days of first dose of study treatment) use of aspirin (≥ 325 mg/day) or treatment with dipyridamole, ticlopidine, clopidogrel, and cilostazol
• Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purposes is ineligible
• History of significant bleeding disorders, vasculitis, or a significant bleeding episode from the GI tract within 6 months prior to study randomization.
• Participants with untreated or incompletely treated varices with bleeding or high-risk (red wale signs or other high-risk factors) for bleeding.
• HCC related
• Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
• Central nervous system metastases or spinal cord compression (including asymptomatic and adequately treated disease)
• Prior treatment with anti-CTLA-4 and/or anti-TIGIT.
• Radiotherapy within 28 days and abdominal/ pelvic radiotherapy within 60 days prior to initiation of study treatment, except palliative radiotherapy to bone lesions within 7 days prior to initiation of study treatment

Where it is running

• Research Site — Milwaukee, Wisconsin, United States (enrolling)
• Research Site — Barretos, Brazil (enrolling)
• Research Site — Amarillo, Texas, United States (enrolling)
• Research Site — Salem, Virginia, United States (enrolling)
• Research Site — Camperdown, Australia (enrolling)
• Research Site — Heidelberg, Australia (enrolling)
• Research Site — Tucson, Arizona, United States (enrolling)
• Research Site — Palo Alto, California, United States (enrolling)
• Research Site — Houston, Texas, United States (enrolling)
• Research Site — Arlington, Virginia, United States (enrolling)
• Research Site — Auchenflower, Australia (enrolling)
• Research Site — Phoenix, Arizona, United States (enrolling)
• Research Site — Jacksonville, Florida, United States (enrolling)
• Research Site — Grand Rapids, Michigan, United States (enrolling)
• Research Site — Rochester, Minnesota, United States (enrolling)
• Research Site — Atlanta, Georgia, United States (enrolling)
• Research Site — New Brunswick, New Jersey, United States (enrolling)
• Research Site — New York, New York, United States (enrolling)
• Research Site — New Haven, Connecticut, United States (enrolling)
• Research Site — Austin, Texas, United States (enrolling)
• Research Site — San Antonio, Texas, United States (enrolling)
• Research Site — Tyler, Texas, United States (enrolling)
• Research Site — Newark, Delaware, United States (enrolling)
• Research Site — Pittsburgh, Pennsylvania, United States (enrolling)
• Research Site — Porto Alegre, Brazil (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.